skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Review of early Cf-252 trials and the Lexington experience

Journal Article · · Nucl. Sci. Appl.; (United States)
OSTI ID:6698926

In the early Cf-252 brachytherapy trials, the M.D. Anderson Hospital, Churchill Hospital in Oxford, England and the Memorial Sloan-Kettering Cancer Center treated a total of 53 tumors in a similar number of patients in early Phase I trials. This group of patients had mostly metastatic, recurrent, persistent, or multiple metastatic tumors. Only 20 patients had primary tumors of which 8 were of skin origin. There were 3 melanomas/sarcomas which would do poorly regardless of therapy. The remaining tumors were of many different sites. Estimates of RBE were determined in relation to Ir-192 and indicated a value of 6.0-7.5. The early trials were terminated before any real assessment of efficacy of Cf therapy was possible. The fact that the trials were abandoned greatly hindered support for later trials. The Lexington, Kentucky trials have treated --500 patients of which 306 were primary tumors of the cervix, uterus, or vagina. These later experiences have been the basis of an emerging understanding of Cf-252 for cancer therapy.

Research Organization:
Radiation Therapy Oncology Center, Univ. of Kentucky Medical Center, Lexington, KY
OSTI ID:
6698926
Journal Information:
Nucl. Sci. Appl.; (United States), Vol. 2:3
Country of Publication:
United States
Language:
English

Similar Records

Brachytherapy with Cf-252 in USSR: Head and neck, GYN and other tumors
Journal Article · Wed Jan 01 00:00:00 EST 1986 · Nucl. Sci. Appl.; (United States) · OSTI ID:6698926

Lexington studies of Cf-252 brachytherapy for advanced cervical and uterine cancer
Journal Article · Wed Jan 01 00:00:00 EST 1986 · Nucl. Sci. Appl.; (United States) · OSTI ID:6698926

Experience with and potential of Cf-252 therapy for other tumors: Lexington clinical trials
Journal Article · Wed Jan 01 00:00:00 EST 1986 · Nucl. Sci. Appl.; (United States) · OSTI ID:6698926